Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.

Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H.

Neurol Genet. 2018 Oct 5;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct.

PMID:
30338293
2.

Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease.

Houser MC, Chang J, Factor SA, Molho ES, Zabetian CP, Hill-Burns EM, Payami H, Hertzberg VS, Tansey MG.

Mov Disord. 2018 May;33(5):793-804. doi: 10.1002/mds.27326. Epub 2018 Mar 23.

PMID:
29572994
3.

Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease.

Hui KY, Fernandez-Hernandez H, Hu J, Schaffner A, Pankratz N, Hsu NY, Chuang LS, Carmi S, Villaverde N, Li X, Rivas M, Levine AP, Bao X, Labrias PR, Haritunians T, Ruane D, Gettler K, Chen E, Li D, Schiff ER, Pontikos N, Barzilai N, Brant SR, Bressman S, Cheifetz AS, Clark LN, Daly MJ, Desnick RJ, Duerr RH, Katz S, Lencz T, Myers RH, Ostrer H, Ozelius L, Payami H, Peter Y, Rioux JD, Segal AW, Scott WK, Silverberg MS, Vance JM, Ubarretxena-Belandia I, Foroud T, Atzmon G, Pe'er I, Ioannou Y, McGovern DPB, Yue Z, Schadt EE, Cho JH, Peter I.

Sci Transl Med. 2018 Jan 10;10(423). pii: eaai7795. doi: 10.1126/scitranslmed.aai7795.

4.

The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.

Payami H.

Mov Disord. 2017 Aug;32(8):1139-1146. doi: 10.1002/mds.27099. Epub 2017 Jul 7. Review.

5.

Caffeine, creatine, GRIN2A and Parkinson's disease progression.

Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T.

J Neurol Sci. 2017 Apr 15;375:355-359. doi: 10.1016/j.jns.2017.02.032. Epub 2017 Feb 17.

6.

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H.

Mov Disord. 2017 May;32(5):739-749. doi: 10.1002/mds.26942. Epub 2017 Feb 14.

7.

Identification of genetic modifiers of age-at-onset for familial Parkinson's disease.

Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD, Ritz B, Scherzer CR, Zabetian CP, Factor SA, Breheny PJ, Payami H.

Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11.

8.

DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.

Wang L, Maldonado L, Beecham GW, Martin ER, Evatt ML, Ritchie JC, Haines JL, Zabetian CP, Payami H, Pericak-Vance MA, Vance JM, Scott WK.

Neurol Genet. 2016 Apr 12;2(3):e72. doi: 10.1212/NXG.0000000000000072. eCollection 2016 Jun.

9.

Glutamate receptor gene GRIN2A, coffee, and Parkinson disease.

Hamza TH, Hill-Burns EM, Scott WK, Vance JM, Factor SA, Zabetian CP, Payami H.

PLoS Genet. 2014 Nov 20;10(11):e1004774. doi: 10.1371/journal.pgen.1004774. eCollection 2014 Nov. No abstract available.

10.

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS.

Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065. Epub 2014 Nov 12.

11.

Erratum to "Exploratory analysis of seven Alzheimer's disease genes: disease progression" [Neurobiol. Aging 34 (2013) 1310.e1-1310.e7].

Ruiz A, Hernández I, Ronsende-Roca M, González-Pérez A, Rodriguez-Noriega E, Ramírez-Lorca R, Mauleón A, Moreno-Rey C, Boswell L, Tune L, Valero S, Alegret M, Gayán J, Becker JT, Real LM, Tárraga L, Ballard C, Terrin M, Sherman S, Payami H, López OL, Mintzer JE, Boada M.

Neurobiol Aging. 2014 Nov;35(11):2661. doi: 10.1016/j.neurobiolaging.2014.06.016. Epub 2014 Sep 17. No abstract available.

PMID:
28911722
12.

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB.

Nat Genet. 2014 Sep;46(9):989-93. doi: 10.1038/ng.3043. Epub 2014 Jul 27.

13.

Identification of a novel Parkinson's disease locus via stratified genome-wide association study.

Hill-Burns EM, Wissemann WT, Hamza TH, Factor SA, Zabetian CP, Payami H.

BMC Genomics. 2014 Feb 10;15:118. doi: 10.1186/1471-2164-15-118.

14.

Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective.

Payami H, Factor SA.

Neurotherapeutics. 2014 Jan;11(1):111-6. doi: 10.1007/s13311-013-0237-y. Review.

15.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

16.

Association of Parkinson disease with structural and regulatory variants in the HLA region.

Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos N, Hoglund B, Holcomb C, Donahue RJ, Thomson G, Erlich H, Payami H.

Am J Hum Genet. 2013 Nov 7;93(5):984-93. doi: 10.1016/j.ajhg.2013.10.009. Epub 2013 Oct 31.

17.

Exploratory analysis of seven Alzheimer's disease genes: disease progression.

Ruiz A, Hernández I, Ronsende-Roca M, González-Pérez A, Rodriguez-Noriega E, Ramírez-Lorca R, Mauleón A, Moreno-Rey C, Boswell L, Tune L, Valero S, Alegret M, Gayán J, Becker JT, Real LM, Tárraga L, Ballard C, Terrin M, Sherman S, Payami H, López OL, Mintzer JE, Boada M.

Neurobiol Aging. 2013 Apr;34(4):1310.e1-7. doi: 10.1016/j.neurobiolaging.2012.08.014. Epub 2012 Oct 1. Erratum in: Neurobiol Aging. 2014 Nov;35(11):2661.

18.

A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.

Hill-Burns EM, Singh N, Ganguly P, Hamza TH, Montimurro J, Kay DM, Yearout D, Sheehan P, Frodey K, McLear JA, Feany MB, Hanes SD, Wolfgang WJ, Zabetian CP, Factor SA, Payami H.

Pharmacogenomics J. 2013 Dec;13(6):530-7. doi: 10.1038/tpj.2012.38. Epub 2012 Oct 2.

19.

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium.

Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687.

20.

Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K.

Neurology. 2012 May 1;78(18):1434-40. doi: 10.1212/WNL.0b013e318253d54b. Epub 2012 Mar 21.

21.

Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.

Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP; 23andMe Genetic Epidemiology of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium; Parkinson's Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2), Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L.

PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.

22.

Evidence for more than one Parkinson's disease-associated variant within the HLA region.

Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H.

PLoS One. 2011;6(11):e27109. doi: 10.1371/journal.pone.0027109. Epub 2011 Nov 9.

23.

Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee.

Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, Tenesa A, Kusel VI, Sheehan P, Eaaswarkhanth M, Yearout D, Samii A, Roberts JW, Agarwal P, Bordelon Y, Park Y, Wang L, Gao J, Vance JM, Kendler KS, Bacanu SA, Scott WK, Ritz B, Nutt J, Factor SA, Zabetian CP, Payami H.

PLoS Genet. 2011 Aug;7(8):e1002237. doi: 10.1371/journal.pgen.1002237. Epub 2011 Aug 18.

24.

An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's disease.

Hill-Burns EM, Hamza TH, Zabetian CP, Factor SA, Payami H.

Eur J Neurol. 2011 Sep;18(9):e107-8; author reply e109. doi: 10.1111/j.1468-1331.2011.03464.x. No abstract available.

25.

Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H.

Mov Disord. 2011 Oct;26(12):2190-5. doi: 10.1002/mds.23806. Epub 2011 Jun 28.

26.

SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP.

Arch Neurol. 2010 Nov;67(11):1350-6. doi: 10.1001/archneurol.2010.279.

27.

Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis.

Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H.

J Neurol Neurosurg Psychiatry. 2011 May;82(5):564-8. doi: 10.1136/jnnp.2010.222042. Epub 2010 Sep 30.

28.

A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.

Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, Samii A, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsi S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H.

Neurology. 2010 Sep 28;75(13):1189-94. doi: 10.1212/WNL.0b013e3181f4d832.

29.

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.

Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H.

Nat Genet. 2010 Sep;42(9):781-5. doi: 10.1038/ng.642. Epub 2010 Aug 15.

30.

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Aasly JO, Vilariño-Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, Johansen KK, Toft M, Nutt JG, Payami H, Kachergus JM, Lincoln SJ, Felic A, Wider C, Soto-Ortolaza AI, Cobb SA, White LR, Ross OA, Farrer MJ.

Mov Disord. 2010 Oct 15;25(13):2156-63. doi: 10.1002/mds.23265.

31.

The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors.

Hamza TH, Payami H.

J Hum Genet. 2010 Apr;55(4):241-3. doi: 10.1038/jhg.2010.13. Epub 2010 Mar 5.

32.

Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease.

Payami H, Kay DM, Zabetian CP, Schellenberg GD, Factor SA, McCulloch CC.

Genet Epidemiol. 2010 Jan;34(1):92-9. doi: 10.1002/gepi.20439.

33.

Genetic association between alpha-synuclein and idiopathic Parkinson's disease.

Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, Leis BC, Nutt JG, Montimurro JS, Keefe RG, Atkins AJ, Yearout D, Zabetian CP, Payami H.

Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1222-30. doi: 10.1002/ajmg.b.30758.

PMID:
18404644
34.

Exploring gene-environment interactions in Parkinson's disease.

McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H.

Hum Genet. 2008 Apr;123(3):257-65. doi: 10.1007/s00439-008-0466-z. Epub 2008 Jan 22.

PMID:
18210157
35.

Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.

Hutter CM, Samii A, Factor SA, Nutt JG, Higgins DS, Bird TD, Griffith A, Roberts JW, Leis BC, Montimurro JS, Kay DM, Edwards KL, Payami H, Zabetian CP.

Eur J Neurol. 2008 Feb;15(2):134-9. Epub 2007 Dec 18.

36.

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.

Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW, Martinez ED, Montimurro JS, Checkoway H, Payami H.

Mov Disord. 2008 Jan;23(1):88-95.

PMID:
17987647
37.

Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease.

Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Kay DM, Yearout D, Montimurro JS, Edwards KL, Samii A, Payami H.

Ann Neurol. 2007 Aug;62(2):137-44.

38.

DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease.

Chun LS, Samii A, Hutter CM, Griffith A, Roberts JW, Leis BC, Mosley AD, Wander PL, Edwards KL, Payami H, Zabetian CP.

Ann Neurol. 2007 Jul;62(1):99-101.

39.

Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, Hinkle KM, Stone JT, Ross OA, Hauser R, Aasly J, Gasser T, Payami H, Wszolek ZK, Farrer MJ.

Neurogenetics. 2007 Apr;8(2):95-102. Epub 2007 Jan 16.

PMID:
17225181
40.

Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.

Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J, Factor SA, Yu CE, Montimurro JS, Keefe RG, Schellenberg GD, Payami H.

Ann Neurol. 2007 Jan;61(1):47-54.

PMID:
17187375
41.

Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.

Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Southwick A, Myers RM, Trikalinos TA.

Lancet Neurol. 2006 Nov;5(11):917-23.

42.

Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease.

Kay DM, Bird TD, Zabetian CP, Factor SA, Samii A, Higgins DS, Nutt J, Roberts JW, Griffith A, Leis BC, Montimurro JS, Philpott S, Payami H.

Genet Test. 2006 Fall;10(3):221-7.

PMID:
17020475
43.

Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease.

Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, Schellenberg GD, Van Deerlin V, Yuan W, Bird TD.

Arch Neurol. 2006 Sep;63(9):1307-11.

PMID:
16966510
44.

LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.

Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H.

Am J Hum Genet. 2006 Oct;79(4):752-8. Epub 2006 Aug 17.

45.

Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.

Zabetian CP, Lauricella CJ, Tsuang DW, Leverenz JB, Schellenberg GD, Payami H.

Arch Neurol. 2006 Jan;63(1):156-7. No abstract available.

46.

Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.

Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, Bird TD, Kramer P, Higgins DS, Payami H.

Mov Disord. 2006 Apr;21(4):519-23.

PMID:
16250030
47.

One step closer to fixing association studies: evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls.

Payami H, Zhu M, Montimurro J, Keefe R, McCulloch CC, Moses L.

Hum Genet. 2005 Dec;118(3-4):322-30. Epub 2005 Sep 28.

PMID:
16189709
48.

Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.

Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H.

Mov Disord. 2005 Aug;20(8):1077-8. No abstract available.

PMID:
16001413
49.

Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations.

Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C, Rajput A.

Mov Disord. 2005 Aug;20(8):989-94.

PMID:
15852364
50.

False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy.

Factor SA, Qian J, Lava NS, Hubbard JD, Payami H.

Ann Neurol. 2005 Mar;57(3):462-3. No abstract available.

PMID:
15732096

Supplemental Content

Loading ...
Support Center